Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 2
2006 1
2012 2
2018 1
2019 55
2020 90
2021 82
2022 77
2023 77
2024 30

Text availability

Article attribute

Article type

Publication date

Search Results

360 results

Results by year

Filters applied: . Clear all
Page 1
Ulcerative Colitis in Adults: A Review.
Gros B, Kaplan GG. Gros B, et al. JAMA. 2023 Sep 12;330(10):951-965. doi: 10.1001/jama.2023.15389. JAMA. 2023. PMID: 37698559 Review.
Moderate to severe UC may require oral corticosteroids for induction of remission as a bridge to medications that sustain remission (biologic monoclonal antibodies against tumor necrosis factor [eg, infliximab], alpha4beta7 integrins [vedolizumab], and interleukin [IL] 12 and IL- …
Moderate to severe UC may require oral corticosteroids for induction of remission as a bridge to medications that sustain remission (biologi …
Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review.
Armstrong AW, Read C. Armstrong AW, et al. JAMA. 2020 May 19;323(19):1945-1960. doi: 10.1001/jama.2020.4006. JAMA. 2020. PMID: 32427307 Review.
Other biologics inhibit cytokines such as the p40 subunit of the cytokines IL-12 and IL-13 (ustekinumab), IL-17 (secukinumab, ixekizumab, bimekizumab, and brodalumab), and the p19 subunit of IL-23 (guselkumab, tildrakizumab, risankizumab, and mirikizumab). ...
Other biologics inhibit cytokines such as the p40 subunit of the cytokines IL-12 and IL-13 (ustekinumab), IL-17 (secukinumab, ixekizu …
British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults.
Lamb CA, Kennedy NA, Raine T, Hendy PA, Smith PJ, Limdi JK, Hayee B, Lomer MCE, Parkes GC, Selinger C, Barrett KJ, Davies RJ, Bennett C, Gittens S, Dunlop MG, Faiz O, Fraser A, Garrick V, Johnston PD, Parkes M, Sanderson J, Terry H; IBD guidelines eDelphi consensus group; Gaya DR, Iqbal TH, Taylor SA, Smith M, Brookes M, Hansen R, Hawthorne AB. Lamb CA, et al. Gut. 2019 Dec;68(Suppl 3):s1-s106. doi: 10.1136/gutjnl-2019-318484. Epub 2019 Sep 27. Gut. 2019. PMID: 31562236 Free PMC article. Review.
IL-12 and IL-23 pathway inhibition in inflammatory bowel disease.
Verstockt B, Salas A, Sands BE, Abraham C, Leibovitzh H, Neurath MF, Vande Casteele N; Alimentiv Translational Research Consortium (ATRC). Verstockt B, et al. Nat Rev Gastroenterol Hepatol. 2023 Jul;20(7):433-446. doi: 10.1038/s41575-023-00768-1. Epub 2023 Apr 17. Nat Rev Gastroenterol Hepatol. 2023. PMID: 37069321 Review.
An increased understanding of these biological effects, particularly the pro-inflammatory effects mediated by IL-12 and IL-23, has led to the development of monoclonal antibodies that target a subunit common to IL-12 and IL-23 (p40; targeted by ustekinumab and briakinumab) …
An increased understanding of these biological effects, particularly the pro-inflammatory effects mediated by IL-12 and IL-23, has led to th …
Ulcerative Colitis-Diagnostic and Therapeutic Algorithms.
Kucharzik T, Koletzko S, Kannengiesser K, Dignass A. Kucharzik T, et al. Dtsch Arztebl Int. 2020 Aug 17;117(33-34):564-574. doi: 10.3238/arztebl.2020.0564. Dtsch Arztebl Int. 2020. PMID: 33148393 Free PMC article. Review.
Further drugs are available to treat patients with a more complicated disease course of ulcerative colitis, including azathioprine, biological agents, JAK inhibitors (among them TNF antibodies, biosimilars, ustekinumab, vedolizumab, and tofacitinib), and calcineurin inhibi …
Further drugs are available to treat patients with a more complicated disease course of ulcerative colitis, including azathioprine, biologic …
Blockade of IL-23: What is in the Pipeline?
Parigi TL, Iacucci M, Ghosh S. Parigi TL, et al. J Crohns Colitis. 2022 May 11;16(Supplement_2):ii64-ii72. doi: 10.1093/ecco-jcc/jjab185. J Crohns Colitis. 2022. PMID: 35553666 Free PMC article. Review.
Interleukin 23 [IL-23] plays a key role in the pathogenesis of both Crohn's disease [CD] and ulcerative colitis [UC], promoting a Th17 cell-related immune response. The combined blockade of IL-23 and IL-12 with ustekinumab has been demonstrated to be safe and effective in …
Interleukin 23 [IL-23] plays a key role in the pathogenesis of both Crohn's disease [CD] and ulcerative colitis [UC], promoting a Th17 cell- …
State-of-the-art treatment of systemic lupus erythematosus.
Tanaka Y. Tanaka Y. Int J Rheum Dis. 2020 Apr;23(4):465-471. doi: 10.1111/1756-185X.13817. Epub 2020 Mar 5. Int J Rheum Dis. 2020. PMID: 32134201 Free PMC article. Review.
At present, many biologicals, such as anifrolumab (anti-type I interferon receptor antibody) and ustekinumab (antibody against interleukin 12/23 [p40]), are in clinical trials. ...
At present, many biologicals, such as anifrolumab (anti-type I interferon receptor antibody) and ustekinumab (antibody against interl …
Treatment Algorithms for Crohn's Disease.
Sulz MC, Burri E, Michetti P, Rogler G, Peyrin-Biroulet L, Seibold F; on behalf of the Swiss IBDnet, an official working group of the Swiss Society of Gastroenterology. Sulz MC, et al. Digestion. 2020;101 Suppl 1:43-57. doi: 10.1159/000506364. Epub 2020 Mar 13. Digestion. 2020. PMID: 32172251 Free article. Review.
New compounds introduced in CD therapy in recent years justify such an update on standard approaches. Ustekinumab and vedolizumab and their positions within the treatment options are discussed. ...Key Messages: In recent years, a variety of new drugs became available to tr …
New compounds introduced in CD therapy in recent years justify such an update on standard approaches. Ustekinumab and vedolizumab and …
New Treatment Addressing the Pathogenesis of Psoriasis.
Tokuyama M, Mabuchi T. Tokuyama M, et al. Int J Mol Sci. 2020 Oct 11;21(20):7488. doi: 10.3390/ijms21207488. Int J Mol Sci. 2020. PMID: 33050592 Free PMC article. Review.
The effectiveness of biologic treatments such as tumor necrosis factor (TNF)alpha inhibitors (infliximab, adalimumab, certolizumab pegol), IL23 inhibitors (ustekinumab, guselkumab, tildrakizumab, risankizumab), and IL17 inhibitors (secukinumab, ixekizumab, brodalumab) have …
The effectiveness of biologic treatments such as tumor necrosis factor (TNF)alpha inhibitors (infliximab, adalimumab, certolizumab pegol), I …
Is there an optimal sequence of biologic therapies for inflammatory bowel disease?
Bressler B. Bressler B. Therap Adv Gastroenterol. 2023 Apr 5;16:17562848231159452. doi: 10.1177/17562848231159452. eCollection 2023. Therap Adv Gastroenterol. 2023. PMID: 37057077 Free PMC article. Review.
Data from ULTRA 2, GEMINI 1, VARSITY, and True North in patients with ulcerative colitis indicate that induction adalimumab, vedolizumab, and ozanimod showed lower clinical remission rates after anti-TNF therapy, while UNIFI, OCTAVE 1&2, and U-ACHIEVE/U-ACCOMPLISH show ust …
Data from ULTRA 2, GEMINI 1, VARSITY, and True North in patients with ulcerative colitis indicate that induction adalimumab, vedolizumab, an …
360 results